Phil Nadeau
Stock Analyst at TD Cowen
(3.39)
# 999
Out of 4,734 analysts
23
Total ratings
42.86%
Success rate
32.24%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Phil Nadeau
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| KURA Kura Oncology | Reiterates: Buy | n/a | $7.26 | - | 1 | Nov 21, 2024 | |
| SYRS Syros Pharmaceuticals | Downgrades: Hold | n/a | $0.22 | - | 1 | Nov 13, 2024 | |
| RYTM Rhythm Pharmaceuticals | Maintains: Buy | $55 → $65 | $54.54 | +19.18% | 2 | Nov 6, 2024 | |
| BIIB Biogen | Maintains: Buy | $300 → $275 | $140.55 | +95.66% | 6 | Oct 31, 2024 | |
| BMRN BioMarin Pharmaceutical | Maintains: Buy | $125 → $120 | $61.53 | +95.03% | 1 | Aug 6, 2024 | |
| VRTX Vertex Pharmaceuticals | Maintains: Buy | $450 → $500 | $422.00 | +18.48% | 7 | Jul 23, 2024 | |
| ELVN Enliven Therapeutics | Initiates: Outperform | n/a | $21.47 | - | 1 | Mar 3, 2023 | |
| MLTX MoonLake Immunotherapeutics | Initiates: Outperform | n/a | $43.81 | - | 1 | Jul 7, 2022 | |
| AURA Aura Biosciences | Initiates: Outperform | n/a | $7.77 | - | 1 | Nov 23, 2021 | |
| ANNX Annexon | Initiates: Outperform | n/a | $4.20 | - | 1 | Aug 18, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | n/a | $6.19 | - | 1 | Jul 16, 2018 |
Kura Oncology
Nov 21, 2024
Reiterates: Buy
Price Target: n/a
Current: $7.26
Upside: -
Syros Pharmaceuticals
Nov 13, 2024
Downgrades: Hold
Price Target: n/a
Current: $0.22
Upside: -
Rhythm Pharmaceuticals
Nov 6, 2024
Maintains: Buy
Price Target: $55 → $65
Current: $54.54
Upside: +19.18%
Biogen
Oct 31, 2024
Maintains: Buy
Price Target: $300 → $275
Current: $140.55
Upside: +95.66%
BioMarin Pharmaceutical
Aug 6, 2024
Maintains: Buy
Price Target: $125 → $120
Current: $61.53
Upside: +95.03%
Vertex Pharmaceuticals
Jul 23, 2024
Maintains: Buy
Price Target: $450 → $500
Current: $422.00
Upside: +18.48%
Enliven Therapeutics
Mar 3, 2023
Initiates: Outperform
Price Target: n/a
Current: $21.47
Upside: -
MoonLake Immunotherapeutics
Jul 7, 2022
Initiates: Outperform
Price Target: n/a
Current: $43.81
Upside: -
Aura Biosciences
Nov 23, 2021
Initiates: Outperform
Price Target: n/a
Current: $7.77
Upside: -
Annexon
Aug 18, 2020
Initiates: Outperform
Price Target: n/a
Current: $4.20
Upside: -
Jul 16, 2018
Initiates: Outperform
Price Target: n/a
Current: $6.19
Upside: -